- Entry
- $7.68
- Final
- $8.07 +5.1%
- Target
- $20.93
- Score
- +0.03
— ORIGINAL POST ·
A Look At ImmunityBio (IBRX) Valuation After FDA Anktiva Pathway And Saudi Approvals - Result: DCF Fair value of $20.93 (UNDERVALUED)
· r/Shortsqueeze
· Jan 22, 2026